Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad JGH Open.2025;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George Hepatology International.2024; 18(6): 1740. CrossRef
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period Kazuma Mori, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keisuke Endo, Toshifumi Ogawa, Toru Suzuki, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Itaru Hosaka, Araya Umetsu, Nagisa Hanawa, Masato Furuhashi Hepatology Research.2025; 55(1): 34. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An Hepatology Research.2025; 55(9): 1239. CrossRef
Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, M Scientific Reports.2024;[Epub] CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2024;[Epub] CrossRef
Association between fibrosis-4 index (FIB-4) and gallstones: an analysis of the NHANES 2017–2020 cross-sectional study Huqiang Dong, Zufa Zhang, Chang Fu, Mixue Guo, Haifeng Zhang, Xintian Cai, Hongping Cheng BMC Gastroenterology.2025;[Epub] CrossRef
The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial Sung-Min Won, Hyunchae Joung, In Gyu Park, Sang Hak Han, Young Lim Ham, Ji Sook Han, Yoojin Kwon, Dong Joon Kim, Ki Tae Suk Journal of Translational Medicine.2025;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li Clinical and Molecular Hepatology.2024; 30(4): 1019. CrossRef
Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Diabetes & Metabolism Journal.2026; 50(1): 178. CrossRef
Reduced skeletal muscle mass and elevated phase angle are linked to metabolic dysfunction-associated steatotic liver disease in Japanese males Satoko Tajirika, Takao Miwa, Masahito Shimizu, Mayumi Yamamoto Nutrition.2026; : 113118. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2025; 64(9): 1296. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Impact of Continuous Nutritional Counseling on Liver Function and Body Composition in Patients with MASLD/MASH Shiho Asai, Naoto Kawabe, Akemi Ito, Teiji Kuzuya, Eizaburo Ohno, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yuka Ochi, Sayuri Miyaji, Sayaka Morisaki, Yoshiki Hirooka Kanzo.2025; 66(6): 222. CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad JGH Open.2025;[Epub] CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
In-silico identification and experimental validation of shared genes and pathways to decipher the molecular links between COPD and MASLD Anupama Dubey, Praveen Kumar, Tahseen Khan, Suneel Kateriya, Dinesh Mani Tripathi, Umesh C.S. Yadav Computers in Biology and Medicine.2025; 194: 110532. CrossRef
Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction Che-Hao Tseng, Bor-Yang Jou, Hsiao-Chin Shen, Hsiao-Yun Yeh, Shiao-Ya Hong, Yi-Hsuan Lin, Hung-Cheng Tsai, Tzu-Hao Li, Chien-Wei Su, Kun-Ta Chou, Diahn Warng Perng, Ying-Ying Yang, Ming-Chih Hou BMJ Open Respiratory Research.2025; 12(1): e003352. CrossRef
Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults Dayang Zheng, Xiang Liu, Wei Zeng, Wangyan Zhou, Chunxiang Zhou Scientific Reports.2024;[Epub] CrossRef
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Results Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
Citations
Citations to this article as recorded by
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study Qi Feng, Pinelopi Manousou, Chioma N. Izzi-Engbeaya, Mark Woodward Cardiovascular Diabetology.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Alcohol Intake and Cardiometabolic Risk Factors Are Independently Associated With a Higher AST/Platelet Ratio Index in Obese Males Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Tsubasa Tsutsumi, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nakajima, Tomoari Kam Liver International Communications.2025;[Epub] CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez PLOS One.2025; 20(7): e0327772. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators Yoshihiro Kamada, Takunori Sato, Takaomi Kessoku, Yoshio Sumida, Masafumi Ono, Kenji Ryotokuji Laser Therapy.2025;[Epub] CrossRef
Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders Yoshihiro Kamada, Makoto Fujii, Hitoshi Nishizawa, Shiro Fukuda, Makoto Yamada, Iichiro Shimomura, Eiji Miyoshi Hepatology Research.2025;[Epub] CrossRef
Concept, Diagnosis, and Treatment in Steatotic Liver Disease (SLD) Yoshio Sumida, Takaomi Kessoku, Hirotoshi Ebinuma Health Evaluation and Promotion.2025; 52(6): 794. CrossRef
COMBINED DISORDER: CURRENT STATUS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH HYPOTHYROIDISM AND PROSPECTS FOR PATIENT PATHWAY IMPLEMENTATION Valentyna Psarova, Anastasiia Cherkashyna Eastern Ukrainian Medical Journal.2025; 13(3): 593. CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Yeo-Wool Kang, Yang-Hyun Baek, Sang-Yi Moon Diagnostics.2024; 14(22): 2517. CrossRef
Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim Gut and Liver.2024; 18(6): 1048. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease Jun Arai, Akinori Okumura, Satoshi Kimoto, Kazumasa Sakamoto, Tomoya Kitada, Rena Kitano, Tadahisa Inoue, Sayaka Nishimura, Noriko Inden, Yukiko Muraki, Naoya Kato, Kiyoaki Ito Hepatology International.2025; 19(4): 836. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, Chuthathip Kaeosri, Banthoon Sukphutanan, Yanfang Pang, Narathorn Kulthamrongsri, Methasit Jaisa-aad, Cheng Han Ng, Margaret Teng, Masahito Nakano, Asahiro Morishita, Naim Alkhouri, Ju Dong Yang, Metabolism.2024; 158: 155958. CrossRef
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(3): 577. CrossRef
Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy? Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su JGH Open.2024;[Epub] CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
The impact of hepatic steatosis on epicardial adipose tissue in obese individuals Gül Trabzon, Fatma Öztürk Keleş, Osman Fırat Çalışkan, Şükrü Güngör, Nuriye Yarar, Ufuk Utku Güllü Journal of Pediatric Endocrinology and Metabolism.2026; 39(1): 46. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) Yuanfeng Lan, Ran Song, Duiping Feng, Junqi He Scientific Reports.2025;[Epub] CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial Sung-Min Won, Hyunchae Joung, In Gyu Park, Sang Hak Han, Young Lim Ham, Ji Sook Han, Yoojin Kwon, Dong Joon Kim, Ki Tae Suk Journal of Translational Medicine.2025;[Epub] CrossRef
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H Gut Microbes.2024;[Epub] CrossRef
Association of metabolic dysfunction‐associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono, Journal of Gastroenterology and Hepatology.2024; 39(6): 1107. CrossRef
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, Chuthathip Kaeosri, Banthoon Sukphutanan, Yanfang Pang, Narathorn Kulthamrongsri, Methasit Jaisa-aad, Cheng Han Ng, Margaret Teng, Masahito Nakano, Asahiro Morishita, Naim Alkhouri, Ju Dong Yang, Metabolism.2024; 158: 155958. CrossRef
Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease In-gyu Park, Sang Jun Yoon, Sung-min Won, Ki-Kwang Oh, Ji Ye Hyun, Ki Tae Suk, Unjoo Lee Scientific Reports.2024;[Epub] CrossRef
Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy? Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.
Citations
Citations to this article as recorded by
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(1): e38. CrossRef
Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution Fu-Qun Wei, Pei-Shu Huang, Bing Zhang, Rui Guo, Yan Yuan, Jin Chen, Zheng-Yu Lin BMC Cancer.2025;[Epub] CrossRef
Celecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levels Boshi Sun, Yuqiao Zhao, Shifeng Yang, Xiaodong Li, Nana Li, Yujie Wang, Qixiang Han, Xuyun Liu, Qiushi Tu, Jie Zheng, Xinyu Zhang Journal of Hazardous Materials.2025; 489: 137613. CrossRef
Reply: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma Deok Hwa Seo, Pil Soo Sung Hepatology.2025; 81(4): E123. CrossRef
A Chemotherapy Response-Related Gene Signature and DNAJC8 as Key Mediators of Hepatocellular Carcinoma Progression and Drug Resistance Yan Ye, Yanmei Zeng, Shenggang Huang, Chunping Zhu, Qingshui Wang Journal of Hepatocellular Carcinoma.2025; Volume 12: 579. CrossRef
A nomogram based on PNI and preoperative TACE can predict overall survival in patients with larger than 2 cm HCC after hepatectomy Huizhi Zhang, Chunyu Zhang, Run Hu, Kai Lei, Xingxing Wang, Zuojin Liu Updates in Surgery.2025; 77(4): 1113. CrossRef
Hepatocellular Carcinoma: A Comprehensive Review of Pathophysiology, Risk Factors, Diagnosis and Treatment Strategies Vedika N. Dafe, Pooja R. Hatwar , Ravindra L. Bakal , Harshdeep V. Bindod Journal of Drug Delivery and Therapeutics.2025; 15(5): 159. CrossRef
A technological convergence in hepatobiliary oncology: Evolving roles of smart surgical systems Xuanci Bai, Runze Huang, Qinyu Liu, Xin Jin, Lu Wang, Wei Tang, Kenji Karako, Weiping Zhu BioScience Trends.2025; 19(4): 410. CrossRef
Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications Mohammad Sarif Mohiuddin, Noushin Tabassum Neha, Jawad Ul Karim Mahir, Fardin Al Fahad Shakib, Md. Ashraful Alam, Md. Wahiduzzaman, Rashu Barua, Shakila Jahan Shimu, Mahbubur Rahman, Md. Rafin Hossain, Mohammad Hossain Shariare, Mohammad Mohabbulla Mohib, Frontiers in Endocrinology.2025;[Epub] CrossRef
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepato Zha Peng, Yaqiong Wang, Boyu Chen, Zhuangrong Zhu, Chengyi He, Yang Wei, Hai Huang Frontiers in Oncology.2025;[Epub] CrossRef
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Gastro Hep Advances.2024; 3(4): 506. CrossRef
Impact of bile leak on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukum Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang Heliyon.2023; 9(11): e21906. CrossRef
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study Jonathan Abdelmalak, Simone I. Strasser, Natalie Ngu, Claude Dennis, Marie Sinclair, Avik Majumdar, Kate Collins, Katherine Bateman, Anouk Dev, Joshua H. Abasszade, Zina Valaydon, Daniel Saitta, Kathryn Gazelakis, Susan Byers, Jacinta Holmes, Alexander J. Cancers.2023; 15(24): 5741. CrossRef
Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective and contribute to prolonged patient survival, their effects are unsatisfactory for some specific tumor conditions, such as macrovascular invasion. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC. As yet, there is no worldwide consensus recommending HAIC because no high-quality clinical trials have demonstrated its survival benefit. However, clinical evidence is gradually accumulating that shows its survival benefit, and it is recognized as an effective locoregional treatment for advanced HCC. Several HAIC regimens have been reported, including cisplatin monotherapy, cisplatin plus 5-fluorouracil (low-dose FP), lipiodol-suspended FP, and an oxaliplatin-based regimen. We have entered an era of chemo-diversity in the treatment of advanced HCC. This review aimed to clarify the relevance of HAIC in the era of chemo-diversity. We propose a multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy, with the aim of becoming cancer-free through conversion therapy.
Citations
Citations to this article as recorded by
Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies Henry Sutanto, Galih Januar Adytia, Elisa Elisa, Ummi Maimunah Cancer Pathogenesis and Therapy.2026; 4(1): 1. CrossRef
GLS1 inhibitor CB-839 inhibits the malignant progression of 5-FU resistant hepatoma cells by regulating glutamine metabolism Hao Wang, Xiao-yan Wang, Jian-bo Ji, Zong-xue Zheng, Peng-fei Shang, Xiu-li Guo Chemico-Biological Interactions.2026; 423: 111812. CrossRef
Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature Li Zhang, Pan Xiao, Lian-Dong Shi, Ke-Xin Chen, You-Fu Bing World Journal of Gastrointestinal Oncology.2026;[Epub] CrossRef
The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors Yi Fang, Bo Lao, Wenjia Fang Discover Oncology.2026;[Epub] CrossRef
Fully active zinc nitroprusside nanomedicine transforms cisplatin into chemoimmunotherapeutic agent for robust hepatocellular carcinoma therapy Xuqi Peng, Yating Zheng, Xiran Gui, Xiaomin Liu, Zhenwen Zhao, Yihang Yuan, Yisheng Peng, Haitao Cai, Jinyang Wang, Jianlin Ge, Hui Liu, Haitian Tang, Fan Dai, Aijun Jiang, Ruirui Fan, Yesi Shi, Chengchao Chu, Pan He, Yang Zhang, Gang Liu Cell Biomaterials.2026; : 100338. CrossRef
Deep learning techniques for using computed tomography imaging for hepatocellular carcinoma diagnosis, treatment and prognosis Yao Chen, Qiang Zhang, Ming-Yang Zhang World Journal of Gastroenterology.2026;[Epub] CrossRef
Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma Zeping Yang, Yuanqing Wu, Feizhi Kong, Yue Zhang, Lijun Jia, Chu Tang, Fu Wang Journal of Medicinal Chemistry.2026;[Epub] CrossRef
Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Peng Jiang, Chao Chen, Jing Tian, Fan Yang, Zhen-yu Jiang, An-xiang Hu, Bin Liu Academic Radiology.2025; 32(8): 4595. CrossRef
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way? Stefan Patauner, Giovanni Scotton, Francesca Notte, Antonio Frena World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion Shuangyan Tang, Feng Shi, Yi Xiao, Hongjie Cai, Ping Ma, Yuanmin Zhou, Zhiqiang Wu, Song Chen, Wenbo Guo Hepatology International.2025; 19(1): 106. CrossRef
Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma Huangpeng Lin, Zexian Ma, Jin Li, Heping Zhu, Xuefeng Huang, Huimin Chen, Liang Tu, Yifan Lian, Yongjie Su Frontiers in Immunology.2025;[Epub] CrossRef
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis Wangyi Xuan, Xiaoming Zhang, Yingying Fang, Yueming Zhang, Zhiyi Xiang, Yifei Yu, Qingping Wu, Xingfen Zhang Oncology Letters.2025;[Epub] CrossRef
Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos E Koumarelas World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway Hua Xiao, Zhaoying Yao, Tao Li, Xin Fang, Xuejiao Xu, Sheng Hu, Ya Yang, Chenchen Jin, Yuxiang Fei, Chao Liu, Qianming Du International Immunopharmacology.2025; 150: 114259. CrossRef
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis Lingling Zhao, Cheng Xu, Jiewen Deng, Yang Ni Frontiers in Oncology.2025;[Epub] CrossRef
Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment Kristin E. Goodsell, Alice J. Tao, James O. Park Frontiers in Surgery.2025;[Epub] CrossRef
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review Ying Wu, Zhenpeng Zeng, Shuanggang Chen, Danyang Zhou, Gangling Tong, Duanming Du Frontiers in Immunology.2025;[Epub] CrossRef
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023 Qi-Feng Chen, Xiong-Ying Jiang, Min-Shan Chen, Ning Lyu, Ming Zhao Annals of Surgery Open.2025; 6(1): e562. CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching Qunfang Zhou, Hui Li, Ye Liang, Ruixia Li, Xiaohui Wang, Wei Wang, Mingyu Liu, Feng Duan, Zhimei Huang La radiologia medica.2025; 130(5): 662. CrossRef
Future perspectives on immunotherapy for hepatocellular carcinoma Landon L. Chan, Stephen L. Chan Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Novel multimodal analgesic regimen for perioperative pain management after hepatic artery infusion chemotherapy in patients with advanced hepatocellular carcinoma Jing Yan, Rui An, Jing-Jing Wang, Min Wang, Qi Zhao, Shen Zhao, Jian Xu World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma Xing-Yan Le, Jun-Bang Feng, Xiao-Li Yu, Sui-Li Li, Xiaocai Zhang, Jiaqing Li, Chuan-Ming Li BMC Gastroenterology.2025;[Epub] CrossRef
Natural born Killers: Harnessing NK cells to treat cancer Kanchi Patell, Katherine Myers, Amr Mohamed, David Wald, J. Eva Selfridge Best Practice & Research Clinical Haematology.2025; 38(3): 101630. CrossRef
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging Weihao Zhang, Xiaohui Zhao, Wei Gao, Tongguo Si, Qiang Zou, Xueling Yang, Wenge Xing, Haipeng Yu Frontiers in Immunology.2025;[Epub] CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning Fan Yao, Jianliang Miao, Bing Quan, Jinghuan Li, Bei Tang, Shenxin Lu, Xin Yin Journal of Hepatocellular Carcinoma.2025; Volume 12: 1111. CrossRef
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study Mao-Yuan Mu, Zi-Xiong Chen, Yu-Zhe Cao, Xiao-Bo Fu, Li-Jie Qiu, Han Qi, Fei Gao Cancer Letters.2025; 628: 217851. CrossRef
Comprehensive multi-omics analysis of bile acid metabolism in hepatocellular carcinoma: implications for prognosis, immune microenvironment, and therapeutic resistance Jiayan Ma, Ming Cheng, Limin Jin, Yong Wang, Zhengyang Feng, Yuntian Shen, Yaqun Zhu, Qiliang Peng Clinical and Translational Oncology.2025; 27(12): 4430. CrossRef
Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study Qiuhan Heng, Ying Leng, Gang Bai, Hua Yu Medicine.2025; 104(24): e42834. CrossRef
Combining Hepatic Arterial Interventional Therapies with Lenvatinib and Programmed Cell Death-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Center, Real-World Study Xuehan Shen, Tianyin Shao, Jun Yu, Zhiwei Zhang Journal of Hepatocellular Carcinoma.2025; Volume 12: 1267. CrossRef
Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma Yangshuo Xia, Wu Wen, Yangyu Liao, Yingxiao Cai, Renhua Wan Journal of Hepatocellular Carcinoma.2025; Volume 12: 1425. CrossRef
Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma Hai Huang, Wang Peng, Qiaodan Zhou, Yuchong Zhao, Luyao Liu, Haochen Cui, Jingwen Liang, Mengdie Cao, Wei Chen, Ronghua Wang, Shiru Chen, Si Xiong, Bin Cheng, Shuya Bai Cell Communication and Signaling.2025;[Epub] CrossRef
Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study Jienan Lu, Lusha Zhou, Shuai Zhang, Junxiu Li, Tanrong Liu, Bingying Huang Journal of Surgical Oncology.2025; 132(5): 917. CrossRef
Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort Yangyang Ou, Yiyu Chen, Kang Chen, Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan The American Journal of Surgery.2025; 250: 116602. CrossRef
Efficacy of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma: a comparison with transarterial chemoembolization combined with TKIs Lei Fan, Lei Wang Acta Radiologica.2025; 66(12): 1311. CrossRef
Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma Shuirong Lin, Zimin Song, Peizhe Chen, Xi Yu, Wenxuan Xie, Yunpeng Hua, Shaoqiang Li, Shunli Shen, Ming Kuang Liver Cancer.2025; : 1. CrossRef
PARK7-driven IGF2BP3–K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma Zhiwen Zhu, Xinyu Xia, Yuanxiang Lu, Danfeng Li, Xincheng He, Baohua Zhang, Ge Xiong, Wanguang Zhang, Huifang Liang, Hong Zhu Redox Biology.2025; 87: 103869. CrossRef
FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level Yuan Li, Wenna Liu, Xushen Fan, Xinyi Wu, Mingbo Cao, Xiuling Li, Amin Wurita, Suofeng Sun Journal of Translational Medicine.2025;[Epub] CrossRef
The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma Tianyu Ma, Feilong Zhao, Linmei Yao, Chuanchun Mao, Yuan Tian, Youyou Ma, Fanyun Kong, Ruyu Liu Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis Yangyang Li, Danchen Wang, Fengtao Zhang, Xiang Zheng, Yipei Song, Yang Ran, Xiangran Cai Frontiers in Immunology.2025;[Epub] CrossRef
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma Yi-Min Zhang, Xin-Tong Wu, Jun-Zhe Yi, Jie Xu, Yu-Nan Zhang, Ning Lyu, Ming Zhao Liver Cancer.2025; 14(5): 620. CrossRef
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepato Zha Peng, Yaqiong Wang, Boyu Chen, Zhuangrong Zhu, Chengyi He, Yang Wei, Hai Huang Frontiers in Oncology.2025;[Epub] CrossRef
Consensus Integration of Multiomics Data With Machine Learning Algorithms Reveals Heterogeneous Molecular Subtypes and Enables Personalized Treatment Strategies for Hepatocellular Carcinoma Zhipeng Jin, Kun Fang, Xue Zhang, Mengying Song, Hong Jiang, Yefu Liu, Sujit Nair Human Mutation.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report Jiaxuan Liu, Zichun Zhao, Yulong Tian, Haibo Shao Discover Oncology.2025;[Epub] CrossRef
Conversion Therapy and Liver Regeneration in Liver Cancer Xiaoqin Wu Journal of Biosciences and Medicines.2025; 13(12): 374. CrossRef
Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance Jie Gao, Nan Bai, Mingyu Liu, Ninghua Yao, Zhangzhi Tang, Banglong Xu, Weiting Chen, Xuyang He, Jiayu Shao, Saiyan Bian, Hui Zhao, Wenjie Zheng Oncogenesis.2025;[Epub] CrossRef
Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao Cancer Cell International.2024;[Epub] CrossRef
Efficacy and Safety of Hepatic Arterial Infusion Therapy with Cinobufacini in Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Retrospective Cohort Study Tao Xue, Hongbin Yu, Wenming Feng, Yao Wang, Shiyong Wu, Lili Wang, Peiqin Zhu, Jianming Guan, Quan Sun Cancer Management and Research.2024; Volume 16: 163. CrossRef
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang Cancer Science.2024; 115(7): 2159. CrossRef
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Suho Kim, Jung Suk Oh, Ho Jong Chun, Pil Soo Sung Abdominal Radiology.2024; 49(9): 3127. CrossRef
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Gastro Hep Advances.2024; 3(4): 506. CrossRef
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung Oncology Letters.2024;[Epub] CrossRef
Combining liver-directed and immunotherapy in advanced hepatocellular carcinoma: A review and future directions Pranav Kumar, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Rebecca Panconesi, Mingyi Zhang, Noah X. Tocci, Hanna Hong, Abby Gross, Erlind Allkushi, Maureen Whitsett Linganna, Andrea Schlegel, Toms Augustin, Charles Miller, David CH Kwon, Kazunari Sasaki, Fed Surgical Oncology Insight.2024; 1(4): 100100. CrossRef
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy Eda Caliskan Yildirim, Yakup Ergun World Journal of Gastrointestinal Oncology.2024; 16(12): 4757. CrossRef
Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung Frontiers in Oncology.2024;[Epub] CrossRef
Bavachin stimulates ferroptosis and reduces malignant phenotype progression of hepatocellular carcinoma cells by inducing lipid peroxidation by modulation of the Nrf2/HO-1 signaling pathway Haoyu Li American Journal of Translational Research.2024; 16(11): 6925. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer Wenli Lin, Zhongxian Huang, Zhenhua Du, Yunshan Wang, Taiyang Zuo Frontiers in Oncology.2023;[Epub] CrossRef
Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono The Journal of Dermatology.2026; 53(2): 237. CrossRef
Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index Umut Bakay, Tugba Izci Duran, Ozge Sevil Karstarli Bakay, Rahime Ekmekcioglu Dermatology Practical & Conceptual.2026; 16(1): 6746. CrossRef
Effects of Biologics on Fibrosis-4 Index in Patients with Psoriasis Takashi Morita, Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2025; 92(1): 88. CrossRef
Effects of Guselkumab on the FIB‐4 Index in Psoriasis Patients (EGIPT): A Three‐Year Study Edoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Claudia Paganini, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo The Journal of Dermatology.2025; 52(6): 1113. CrossRef
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma Baiyi Liu, Xiaoxiao Wang, Nan Wu, Feng Liu, Huiying Rao Current Medicinal Chemistry.2025; 32(23): 4786. CrossRef
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review Ilias D. Vachliotis, Stergios A. Polyzos Current Obesity Reports.2025;[Epub] CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study Saori Takamura, Souichiro Saito, Sora Sugai, Yuki Shiko, Takumi Yamaguchi, Yohei Kawasaki, Tomoo Fukuda The Journal of Dermatology.2025; 52(12): 1796. CrossRef
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan Katya Meridor, Stephanie R Harrison, Richard Parker, Chenchu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston Rheumatology.2025;[Epub] CrossRef
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. Gottlieb Journal of the American Academy of Dermatology.2024; 91(2): 281. CrossRef
Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not interleukin‐17 inhibitors Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Hideaki Uchida, Chika Chijiwa, Yoshiki Okada, Saori Azuma, Mayumi Nagata, Shota Egawa, Azusa Hiura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa The Journal of Dermatology.2024; 51(9): 1216. CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
Evolution of FIB-4 score in SpA and PsA patients taking anti-TNF or anti-IL17 Frank Verhoeven, Clément Prati, Vincent Di Martino, Thierry Thevenot, Céline Demougeot, Daniel Wendling, Delphine Weil-Verhoeven Joint Bone Spine.2024; 91(6): 105763. CrossRef
Application of graph theory in liver research: A review Xumei Hu, Longyu Sun, Rencheng Zheng, Xueqin Xia, Meng Liu, Weibo Chen, Xinyu Zhang, Chengyan Wang Portal Hypertension & Cirrhosis.2024; 3(4): 234. CrossRef
Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2024; 91(6): 534. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao Frontiers in Immunology.2023;[Epub] CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit Frontiers in Medicine.2022;[Epub] CrossRef
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.
Citations
Citations to this article as recorded by
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2025; 64(9): 1296. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism Irene Tizianel, Alberto Madinelli, Filippo Crimì, Mattia Barbot, Simona Censi, Chiara Sabbadin, Filippo Ceccato Clinical Endocrinology.2025; 102(6): 618. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef
A vegetarian diet improves hepatic steatosis in MASLD patients through weight loss: a randomized controlled trial in China Xiaomeng Mao, Kaijie Xu, Cenyu Wang, Xintong Lu, Xinyuan Yao, Fangfang Song, Zhiping Yu, Linxi Qian, Yi Feng, Xiuhua Shen Food & Function.2025; 16(19): 7678. CrossRef
Emerging roles of stress granules in liver diseases: a comprehensive review Qianyun Zhang, Yun Liu, Junzhe Tang, Ming Li, Qiang Jia Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Prevalence of Non-alcoholic Fatty Liver Disease Detected by Computed Tomography in the General Population Compared with Ultrasonography Yuki Ito, Kentaro Yoshioka, Kazuhiko Hayashi, Yuko Shimizu, Ryo Fujimoto, Ryosuke Yamane, Michiyo Yoshizaki, Go Kajikawa, Taro Mizutani, Hidemi Goto Internal Medicine.2024; 63(2): 159. CrossRef
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study Shuhei Fukunaga, Michita Mukasa, Tomoyuki Nakane, Dan Nakano, Tsubasa Tsutsumi, Tomonori Chou, Hiroshi Tanaka, Daiki Hayashi, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Toshihiro Araki, Tak Hepatology Research.2024; 54(2): 201. CrossRef
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Yasuyo Morita, Yoichi Yano, Hiroki Nakamura, Satoshi Itano, Ichiro Miyajima, Miki Shirachi, Reiichiro Kuwahara, Miki Ohno, Toshihiro Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Teruko Arin Hepatology Research.2024; 54(4): 326. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim Gut.2024; 73(3): 533. CrossRef
Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease Tyng‐Yuan Jang, Chi‐Chang Ho, Po‐Cheng Liang, Chih‐Da Wu, Yu‐Ju Wei, Pei‐Chien Tsai, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Meng‐Hsuan Hsieh, Chih‐Wen Wang, Jeng‐Fu Yang, Ming‐Lun Yeh, Chung‐Feng Huang, Wan‐Long Chuang, Jee‐Fu Huang, Ya‐Yun Cheng, Chia‐ The Kaohsiung Journal of Medical Sciences.2024; 40(3): 304. CrossRef
Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma Ji-Qiao Zhu, Xiao-Yong Ye, Shi-Wei Yang, Jia-Zong Liu, Zhang-Yong Ren, Ya-Nan Jia, Zhe Liu, Cheng Ding, Jian-Tao Kou, Xian-Liang Li, Dong-Dong Han, Qiang He European Journal of Clinical Nutrition.2024; 78(2): 107. CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef
Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer Tomoyuki Nakane, Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Hiroshi Tanaka, Tomonori Chou, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Shinobu Yoshinaga, Michita Mukasa, Yoshinobu Okabe, Hepatology Research.2024; 54(6): 540. CrossRef
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H Gut Microbes.2024;[Epub] CrossRef
Association between life’s essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults Zheng Wang, Bohan Huang, Yixuan Ding, Feng Cao, Fei Li, Prof Fei Li Archives of Public Health.2024;[Epub] CrossRef
Translational research on drug development and biomarker discovery for hepatocellular carcinoma Valerie Chew, Chien-Huai Chuang, Chiun Hsu Journal of Biomedical Science.2024;[Epub] CrossRef
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng BMC Public Health.2024;[Epub] CrossRef
Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups Tatsuya Fukuda, Takahiro Okamoto, Takahiro Fukaishi, Akio Kawakami, Makoto Tanaka, Tetsuya Yamada, Koshiro Monzen Frontiers in Endocrinology.2024;[Epub] CrossRef
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam Annals of Hepatology.2024; 29(5): 101512. CrossRef
MAFLD identifies patients with significant hepatic fibrosis better than MASLD Ziyan Pan, Said A. Al-Busafi, Maheeba Abdulla, Yasser Fouad, Giada Sebastiani, Mohammed Eslam Hepatology International.2024; 18(3): 964. CrossRef
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight Ziyan Pan, Maryam Al Khatry, Ming-Lung Yu, Ashok Choudhury, Giada Sebastiani, Saleh A. Alqahtani, Mohammed Eslam Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
MAFLD: from a disease framework to patient care Mohammed Eslam, Jacob George Hepatology International.2024; 18(S2): 823. CrossRef
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George Clinical and Molecular Hepatology.2024; 30(3): 436. CrossRef
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, Hitoshi Obara, Hironori Yamaguchi, Yuko Toyofuku, Fumi Kaneko, Yutaka Seino, Saeko Uchida Journal of Gastroenterology.2024; 59(9): 836. CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Naohiro Wada, Asako Nogami, Hirokazu Takahashi, Atsushi Nakajima Kanzo.2024; 65(9): 420. CrossRef
Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research Yu‐Ming Cheng, Tsung‐Han Hsieh, Chia‐Chi Wang, Jia‐Horng Kao JGH Open.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan Takumi Kawaguchi, Yoshiyuki Fujishima, Daisuke Wakasugi, Fusayo Io, Yuri Sato, Saeko Uchida, Yukiko Kitajima Journal of Gastroenterology.2024; 59(12): 1120. CrossRef
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation Ling-Ling Wang, Yu-Ming Lu, Yi-Han Wang, Yi-Fan Wang, Rong-Fei Fang, Wen-Li Sai, Deng-Fu Yao, Min Yao World Journal of Gastroenterology.2024; 30(47): 5055. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
Metabolic-associated fatty liver disease and the risk of cardiovascular disease Pengwei Zhang, Xianhui Dong, Wei Zhang, Shiyin Wang, Chen Chen, Jiake Tang, Yao You, Siqi Hu, Shenghui Zhang, Chunyi Wang, Wen Wen, Mengyun Zhou, Tao Tan, Guanming Qi, Li Li, Mingwei Wang Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102063. CrossRef
Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People Naoya Otsubo, Tatsuya Fukuda, Genhin Cho, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen Internal Medicine.2023; 62(16): 2307. CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease Takumi Kawaguchi Kanzo.2023; 64(2): 33. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
MAFLD: How is it different from NAFLD? Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives Shang-Chin Huang, Chun-Jen Liu Clinical and Molecular Hepatology.2023; 29(2): 320. CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff Daya Zhang, Lijun Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1221. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis Hong Fan, Zhenqiu Liu, Pengyan Zhang, Sheng Wu, Xinyu Han, Yiwen Huang, Yichen Zhu, Xingdong Chen, Tiejun Zhang Hepatology International.2023; 17(3): 615. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon Journal of Clinical Medicine.2023; 12(9): 3336. CrossRef
Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki Hepatology Research.2023; 53(7): 579. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
MAFLD: an optimal framework for understanding liver cancer phenotypes Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George Journal of Gastroenterology.2023; 58(10): 947. CrossRef
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung Cancers.2023; 15(17): 4233. CrossRef
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez Current Hepatology Reports.2023; 22(4): 221. CrossRef
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao BMC Medicine.2023;[Epub] CrossRef
Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease Kyu Yeon Choi, Tae Yeon Kim, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Jiwoo Lee, Mi Kyung Kwak, Eun‐Gyoung Hong, Yun Mi Choi, Yeonjung Ha Journal of Cachexia, Sarcopenia and Muscle.2023; 14(6): 2747. CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Chi-Ho Lee Primary Care Diabetes.2022;[Epub] CrossRef
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 269. CrossRef
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi, Mohammed Eslam, Shinobu Yoshinaga, Hirohiko Abe, Ryuichi Nouno, Seiya Joh, Keiichi Mitsuyama, Jacob George, Takuji Torimura Hepatology Research.2022; 52(8): 699. CrossRef
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients Susumu Inamine, Masayoshi Kage, Jun Akiba, Takumi Kawaguchi, Sachiyo Yoshio, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Ryuki Hashida, Kouichi Oshiro Hepatology Research.2022; 52(10): 841. CrossRef
MAFLD, patient-centred care, and APASL Shiv K. Sarin, Mohammed Eslam, Jian-Gao Fan, Han-Chieh Lin, Jacob George, Masao Omata Hepatology International.2022; 16(5): 1032. CrossRef
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, Min‐Sun Kwak, Jong In Yang, Su Jin Chung, Jeong Yoon Yim, Ji Won Yoon, Goh Eun Chung Journal of Cachexia, Sarcopenia and Muscle.2022; 13(6): 2953. CrossRef
Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years In-Ho Seo, Hye Sun Lee, Yong-Jae Lee Cardiovascular Diabetology.2022;[Epub] CrossRef
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami Journal of Oncology Pharmacy Practice.2026; 32(1): 24. CrossRef
Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic Options Hiroki Tai, Asahiro Morishita, Tomoko Tadokoro, Kyoko Oura, Rie Yano, Mai Nakahara, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara Nutrients.2026; 18(3): 494. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi Internal Medicine.2025;[Epub] CrossRef
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen Journal of Hematology & Oncology.2024;[Epub] CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Masatoshi Tanaka, Etusko Moriyama, Tomotake Shirono, Kota Takaki, Yu Noda, Masahito Nakano, Mitsutoshi Inoue, Kazuki Tsustumi, Ryoko Kuromatsu, Hironori Koga, Kyoko Higuchi, Taku Journal of Gastroenterology and Hepatology.2023; 38(7): 1140. CrossRef
Correlation between branched-chain amino acids intake and total lymphocyte count in head and neck cancer patients: a cross-sectional study Yosua Yan Kristian, Rahmat Cahyanur, Yohannessa Wulandari, Wina Sinaga, Widjaja Lukito, Findy Prasetyawaty, Wiji Lestari BMC Nutrition.2023;[Epub] CrossRef
The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi Internal Medicine.2025;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Interaction between sarcopenia and nonalcoholic fatty liver disease Sae Kyung Joo, Won Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S68. CrossRef
An ultrasensitive photoelectrochemical assay for tumor necrosis factor-alpha based on hollow CdS cubes as a signal generator and NiCo2O4-Au as a signal extinguisher Yamin Fu, Baohuan Fan, Shenzhen Chang, Dongyu Guo, Fuxiang Wang, Qinhe Pan The Analyst.2023; 148(19): 4746. CrossRef
Role of increased intestinal permeability in the development and progression of liver diseases S. N. Mekhtiyev, O. A. Mekhtiyeva, O. M. Berko, A. M. Kolodkin Experimental and Clinical Gastroenterology.2023; (12): 130. CrossRef
First
Prev
